ClinicalTrials.gg
CompletedNCT06799416Updated Sep 18, 2025

A Study to Assess the Safety of ARGX-109 in Healthy Volunteers

A Phase 1 interventional study of ARGX-109 and Placebo in Healthy Volunteer, sponsored by argenx. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by argenx · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to assess the safety of ARGX-109 in healthy adults. Another aim is to measure the amount of ARGX-109 in the blood over time to learn how it moves through the body and acts in the body. Each participant will remain in the study for approximately 20 weeks.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is aged 18 to 65 years, inclusive, when signing the ICF
  • has a body weight between 50 and 100 kg and a between 18.5 and 30.0 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  • Has any current or past medical or psychiatric condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    ARGX-109

    Participants receiving the experimental drug

    Biological: ARGX-109

  • Placebo comparator
    Placebo

    Participants receiving placebo

    Other: Placebo

Interventions

  • BiologicalARGX-109

    administrations of ARGX-109

  • OtherPlacebo

    administrations of placebo comparator

06

What researchers measure

Primary outcomes

  1. Incidence of AEs, SAEs and AEs leading to discontinuation

    AE: adverse event, SAE: serious adverse event

    Time frame: up to 16 weeks

Secondary outcomes

  1. Cmax

    Time frame: up to 16 weeks

  2. Total IL-6 serum concentrations

    Time frame: up to 16 weeks

  3. Incidence of ADA against ARGX-109 in serum

    ADA: anti-drug antibody

    Time frame: up to 16 weeks

07

Study locations

1 site
  • Altasciences - Montreal - Phase I unit
    Mount Royal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Aug 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Jan 14, 2025
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06799416
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Jan 14, 2025
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Last update
Sep 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion